

OUR SCIENCE 
TAVO SELECT ™ TAVO PRECISE ™ TAVO ELITE ™
OUR PIPELINE 
Disease Focus Pipeline
OUR TEAM 
Management Team Scientific Advisory Board
OUR PARTNERS 
Collaborations Investors
OUR COMPANY
ABOUT US 
News Join Us

info@tavotek.com





BD@tavotek.com Info@tavotek.com



NEWS & Join Us

“The true sign of intelligence is not knowledge but imagination." — Albert Einstein

News

Homepage

A Summary of Tavotek's Presentations at the 2025 AACR Conference

Author:
Origin:
Time of issue:2025-04-27
Views:191

A Summary of Tavotek's Presentations at the 2025 AACR Conference

Author:
Origin:
Time of issue:2025-04-27
Views:191

AACR 20250417.pdf

Previous: None

Next: Tavotek Pivotal Asset Tavo412 Presented at 2025 AAPS National Biotech Conference

Related News

NAVROGEN INC. AND TAVOTEK BIOTHERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO IMPROVE THERAPEUTIC EFFICACY OF ANTIBODY PIPELINE AGENTS

Tavotek Biotherapeutics Announces Completion of Round B Financing with $35 Million

Tavotek Biotherapeutics Named Finalist for 2023 Annual Awards by Life Sciences Pennsylvania

Tavotek Biotherapeutics Announces Formation and Member of Scientific Advisory Board

Tavotek Announces a Research Agreement with Genmab for the Development of Bispecific Antibodies using Genmab's DuoBody® Platform against a Pair of Disease Relevant Targets